Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.
How to Optimize Quality of Life During Thoracic Radiotherapy for LS-SCLC?
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
Twice-Daily Chemoradiotherapy Boosts Survival in Limited-Stage SCLC
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer
The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.
SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer
SBRT achieved a 5-year DFS of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate risk prostate cancer.
Data Favor Twice-Daily vs Once-Daily Chemoradiotherapy in LS-SCLC
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC
Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.
TTFields After SRS Prolongs Intracranial Response in Brain Metastatic NSCLC
The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer
The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.
Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC
No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.
PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer
Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.
Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer
Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.
ASTRO Guideline Recommends EBRT for Symptomatic Bone Metastases
ASTRO assembled a task force to create a guideline for the administration of palliative external beam radiation therapy for patients with symptomatic bone metastases.
Further Research May Explore Systemic Therapy Failure Following RT in NSCLC
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Data Show Increasing Systemic Therapy Use in NSCLC Radiotherapy Population
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Reflexology Program May Have Use in Integrative Breast Cancer Care
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA Clearance Confers Responses to Radiation in Gynecologic Malignancies
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Complete Consolidative Radiotherapy May Have Survival Benefits in ES-SCLC
Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.
Assessing ctDNA as a Predictor of RT Responses in Gynecologic Cancers
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Reflexology Reduces Stress/Pain, Increases Energy During Breast Cancer RT
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Evaluating Reflexology Impact on Breast Cancer RT-Related Anxiety, Pain
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
RT May Affect Scholastic Performance in Pediatric Brain Tumor Survivors
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
RT Therapy for Brain Tumors May Negatively Impact Processing Speed
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Taste Change Data May Inform Radiotherapy Strategy in Head and Neck Cancer
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Evaluating Scholastic Performance in Brain Cancer Survivors Following RT
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
Data Show Substantial Taste Changes in Head and Neck Cancer Following RT
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Measuring Objective Taste Changes in Head and Neck Cancer Population After RT
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
Radiotherapy/CAR T Combo May be “Great Option” in Relapsed/Refractory DLBCL
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
